Cencora, Inc. (NYSE:COR) Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. lessened its position in shares of Cencora, Inc. (NYSE:COR) by 0.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 101,332 shares of the company’s stock after selling 899 shares during the period. Asset Management One Co. Ltd.’s holdings in Cencora were worth $22,808,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of COR. Private Advisor Group LLC acquired a new stake in Cencora in the first quarter valued at $1,479,000. Janney Montgomery Scott LLC acquired a new stake in shares of Cencora during the 1st quarter worth about $9,522,000. Mutual of America Capital Management LLC purchased a new stake in Cencora during the first quarter worth approximately $5,287,000. Financial Counselors Inc. acquired a new position in Cencora in the first quarter valued at approximately $570,000. Finally, Central Pacific Bank Trust Division purchased a new position in Cencora in the first quarter valued at approximately $326,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 0.0 %

Shares of Cencora stock opened at $233.93 on Wednesday. The company has a market cap of $46.10 billion, a P/E ratio of 25.40, a PEG ratio of 1.49 and a beta of 0.44. The firm has a fifty day moving average of $231.39 and a two-hundred day moving average of $230.54. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora, Inc. has a one year low of $191.11 and a one year high of $247.66.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Bank of America reiterated a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Evercore ISI decreased their target price on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. JPMorgan Chase & Co. lifted their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Leerink Partners lowered their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Finally, Robert W. Baird reduced their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $259.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.